🔴 Outlook Therapeutics is trading 27.16% down today after pricing a discounted $55 million stock-and-warrant offering

Outlook Therapeutics is trading at $0.80 (-27.16%) after pricing 55.6 million shares with accompanying warrants at $0.99, below the $1.10 August 12 close.

• The financing is expected to raise approximately $55 million for the U.S. launch of LYTENAVA and general corporate purposes, but creates substantial dilution.
• The move follows management’s reported $11.2 million cash balance and runway into September, increasing financing urgency.